Earendil Labs reports $787m raised across financing rounds
The AI-driven biologics developer plans to expand research teams and advance its antibody pipeline.
Earendil Labs said on March 20, 2026, that it had raised $787 million across financing rounds. The announcement named Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi and Biotech Development Fund among its backers, without separating the amounts raised in individual rounds.
The company plans to scale its AI-driven biologics research, expand scientific and translational teams, and advance internal programs toward clinical milestones. Its approach combines computational protein design with experimental validation.
Earendil also works with Sanofi through licensing and research collaborations on autoimmune and inflammatory disease programs.
Use of funds
Advance therapeutic programs and expand research and development